Skip to main content
. 2022 Nov 6;42(12):1314–1330. doi: 10.1002/cac2.12385

FIGURE 4.

FIGURE 4

Kaplan‐Meier survival curve of progression‐free survival in the full‐analysis set. The median PFS was 4.30 (95% CI, 4.04‐5.78) and 2.79 (95% CI, 1.91‐3.19) months in the sintilimab and docetaxel arms, respectively. Sintilimab demonstrated significant improvement of PFS over docetaxel (HR: 0.52; 95% CI, 0.39‐0.68; P < 0.001).

Abbreviations: PFS, progression‐free survival; CI, confidence interval; HR, hazard ratio